Replimune Group, Inc. (NASDAQ:REPL) Receives $4.75 Consensus Target Price from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has received a consensus recommendation of “Reduce” from the ten brokerages that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $4.75.

A number of research firms recently commented on REPL. BMO Capital Markets cut Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Replimune Group in a report on Monday, April 13th. Wall Street Zen cut Replimune Group from a “sell” rating to a “strong sell” rating in a report on Saturday, April 25th. Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Friday, April 10th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th.

Insider Buying and Selling

In related news, insider Christopher Sarchi sold 6,500 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider directly owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC purchased a new position in Replimune Group in the 4th quarter worth approximately $29,000. CWM LLC lifted its holdings in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Replimune Group in the 2nd quarter worth approximately $69,000. Finally, Russell Investments Group Ltd. increased its stake in Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after acquiring an additional 7,569 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

NASDAQ REPL opened at $5.01 on Friday. Replimune Group has a 12 month low of $1.50 and a 12 month high of $13.24. The stock has a market cap of $413.68 million, a price-to-earnings ratio of -1.46 and a beta of 0.12. The company’s 50 day moving average is $5.30 and its two-hundred day moving average is $7.50. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.